Antibody against affinity complex

Patent metadata

Field	Value
Publication number	US-9599608-B2
Application number	US-201214346615-A
Country	US
Kind code	B2
Filing date	Jul 4, 2012
Priority date	Sep 21, 2011
Publication date	Mar 21, 2017
Grant date	Mar 21, 2017

Abstract

The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).

First claim

The invention claimed is:

1. An isolated full-length antibody capable of specifically binding to an affinity complex,
wherein the antibody has a variable region of a chicken IgM,
wherein the affinity complex comprises a small substance and an antibody specifically binding to the small substance, and
wherein the small substance is any one of
25OH vitamin D3; or
25OH vitamin D2;
wherein binding rate of the full-length antibody to an affinity complex comprising 1,25(OH) 2 vitamin D3 or 1,25(OH) 2 vitamin D2 and an anti-25OH vitamin D3 antibody or an anti-25OH vitamin D2 antibody is 10% or less as compared to 100% binding rate of the full-length antibody to said affinity complex comprising the small substance and the antibody specifically binding to the small substance.

2. The isolated full-length antibody according to claim 1 , wherein the antibody is produced by a method comprising culturing a DT40 cell having an ability to produce the antibody capable of specifically binding to the affinity complex, to obtain the isolated full-length antibody.

3. The isolated full-length antibody according to claim 1 , wherein the isolated full-length antibody specifically binds to an affinity complex comprising the small substance 25OH vitamin D3 and an anti-25OH vitamin D3 antibody and wherein
the binding rate of the isolated full-length antibody to an affinity complex comprising 1,25(OH) 2 vitamin D3 and an anti-25OH vitamin D3 antibody or an anti-25OH vitamin D2 antibody or an affinity complex comprising 1,25(OH) 2 vitamin D2 and the anti-25OH vitamin D3 antibody or the anti-25OH vitamin D2 antibody is 10% or less as compared to 100% binding rate of the isolated full-length antibody specifically binding to the affinity complex comprising the 25OH vitamin D3 and the anti-25OH vitamin D3 antibody.

4. The isolated full-length antibody according to claim 1 , wherein the isolated full-length antibody specifically binds to an affinity complex comprising the small substance 25OH vitamin D2 and an anti-25OH vitamin D2 antibody and wherein
the binding rate of the isolated full-length antibody to an affinity complex comprising 1,25(OH) 2 vitamin D3 and an anti-25OH vitamin D3 antibody or an anti-25OH vitamin D2 antibody or an affinity complex comprising 1,25(OH) 2 vitamin D2 and the anti-25OH vitamin D3 antibody or the anti-25OH vitamin D2 antibody is 10% or less as compared to 100% binding rate of the isolated full-length antibody specifically binding to the affinity complex comprising the 25OH vitamin D2 and the anti-25OH vitamin D2 antibody.

Assignees

• Omi Kazuya
• Ando Tsuyoshi
• Uchida Yoshiaki
• Goishi Katsutoshi
• Goishi Yoshie
• Oka Asako
• Shirakawa Takashi
• Sakyu Takuya
• Fujirebio Kk

Inventors

• Omi Kazuya
• Ando Tsuyoshi
• Uchida Yoshiaki
• Goishi Katsutoshi
• Oka Asako
• Shirakawa Takashi
• Sakyu Takuya

Classifications

• G01N33/54306 Primary

  Solid-phase reaction mechanisms · CPC title

• C07K16/44

  against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title

• G01N33/82

  involving vitamins {or their receptors} · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title